We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other high growth healthcare stocks.

Global Healthcare Spending Trends and Investment Opportunities

During lean economic times, investing in healthcare stocks is generally regarded as defensive. This is due to the fact that people typically do not cut back on their use of prescription medications or other essential healthcare services, even during difficult financial times. According to the Centers for Medicare and Medicaid Services (CMS), national healthcare spending is projected to reach an estimated $4.8 trillion in 2023 and grow at an annual rate of 5.6% between 2027 and 2032.

Global healthcare spending hit a record high in 2021 at $9.8 trillion, or 10.3% of global gross domestic product (GDP), according to a World Health Organization report released in December 2023. Public health spending, however, continued to rise globally, except for low-income nations, where government health spending fell due to their heavy reliance on foreign assistance. In 2021, high-income countries spent almost $4,000 per capita on health care, while 11% of the world’s population resided in nations that spent less than $50 per person annually. Furthermore, only 0.24% of global health spending went to low-income nations, although making up 8% of the world’s population. According to the report, public spending on health increased significantly during the height of the COVID-19 pandemic, but this growth is unlikely to continue in the long run as nations now prioritize economic issues like high inflation, slowing growth, and rising debt servicing. WHO Assistant Director-General for Universal Health Coverage, Life Course, Dr. Bruce Aylward, stated:

“Sustained public financing on health is urgently needed to progress towards universal health coverage. It is especially critical at this time when the world is confronted by the climate crisis, conflicts and other complex emergencies. People’s health and well-being need to be protected by resilient health systems that can also withstand these shocks.”

This year, the pharmaceutical, medical equipment and supplies, robotics, biotechnology, and neurodegenerative illnesses sub-spaces are the primary ones to watch in the healthcare industry. The emergence and development of glucagon-like Peptide-1 agonists (GLP-1s) is the primary trend of interest in the pharmaceutical industry. These treatments have had a substantial impact on weight loss medications and have completely altered the competitive landscape in this field. Pharmaceutical companies that sell weight-loss medications have also benefited from higher prescription volumes and sales as a result of the development of GLP-1s. For example, BlackRock reported that from 2019 to August 2023, GLP-1 prescription volumes increased at a compound annual growth rate of 45%. The development of Ozempic and Mounjaro, respectively, by top pharmaceutical manufacturers was a major factor in this expansion. Additionally, this has led to a recent increase in the popularity of weight loss medication stocks.

Our Methodology 

For this article, we screened on stocks with a minimum market capitalization of $10 billion and a 5-year average revenue growth of approximately 30%. These stocks were then ranked according to their revenue growth performance.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Revenue Growth: 65.42% 

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is emerging as a high-growth healthcare stock with significant potential for investors.  It is a biopharmaceutical company that specializes in developing RNA interference (RNAi) therapeutics, a novel class of medicines based on Nobel Prize-winning science. The company focuses on creating treatments for rare and severe diseases, as well as more common conditions like high cholesterol.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported strong Q3 2024 financial results, with total product revenue reaching $420 million, a 34% year-over-year increase. Revenue from its TTR franchise totaled $309 million, also up by 34%, while the rare disease franchise generated $111 million, reflecting the same growth rate. The company’s revenue growth was primarily driven by rising patient demand for its marketed products, particularly within the TTR franchise.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is approaching 5,000 patients on treatment with ONPATTRO or AMVUTTRA globally for hATTR polyneuropathy. However, the company estimates that 25,000 to 30,000 patients worldwide suffer from this disease, indicating significant growth potential. The corporation is also preparing for a potential launch in ATTR cardiomyopathy, pending regulatory approval. This expansion could significantly increase Alnylam’s addressable market and drive future growth.

The company is advancing its pipeline with several key developments. It has completed regulatory submissions for vutrisiran in ATTR cardiomyopathy in both the U.S. and EU. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) also initiated a Phase 1 study for ALN-HTT02 targeting Huntington’s disease and reported promising results from a Phase 1 study of mivelsiran for early-onset Alzheimer’s disease. By the end of 2025, the corporation aims to file nine proprietary INDs and potentially 15 new INDs, including partnered programs, significantly expanding its clinical pipeline.

Street analysts have a consensus Moderate Buy rating for the stock, with an average 12-month price target of $313.81. The price target range varies from a low of $205.00 to a high of $400.00, suggesting a potential upside of 28.14% from the stock’s current price of $244.89.

Overall ALNY ranks 5th on our list of the high growth healthcare stocks to invest in now. While we acknowledge the potential of ALNY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ALNY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.